The Association for Diagnostics and Laboratory Medicine (ADLM) conference is one of the world’s largest laboratory medicine conferences. This year’s event, held in partnership with the Canadian Clinical Society of Chemists, took place in Chicago from 27-31 July.
Binding Site, part of Thermo Fisher Scientific, were proud to co-sponsor the Immunology and Infectious Disease Mixer. We hosted three microlectures at the Thermo Fisher Scientific booth. These reflects Thermo Fisher’s commitment to helping you find the tools to advance your lab and shape the future of science.
The three microlectures provided attendees with information on how mass spectrometry can transform protein diagnostics, about the EXENT® System* in particular, and opportunities to increase guideline-compliant testing in Multiple Myeloma diagnosis.
Watch the microlectures below
Significant opportunities for US clinical labs to enhance guideline adherent Multiple Myeloma (MM) diagnostic testing
Presented by Dr Bhrugu Yagnik
The upcoming EXENT® System
Presented by Dr Nick Paciaroni
Mass Spectrometry: Transforming Monoclonal Protein Diagnostics
Presented by Dr Jill Pauli
Conference overview
The conference highlighted new and emerging technologies and value-based testing. Several sessions focussed on how these new technologies can help laboratories demonstrate the value they bring in a time when laboratories are under increasing pressure due to staffing shortages and increased test volumes.
New and emerging testing
A significant area of interest was the use of CSF Kappa Free Light Chains and the Kappa Index as an alternative to oligoclonal band (OCB) testing, which is time-consuming and can sometimes be difficult to interpret. This was echoed by the presentations by Prof. Deisenhammer, Dr. Hegen and Dr. Willrich, who presented the revision of the McDonald Criteria, the diagnostic guideline for Multiple Sclerosis.
Value-based testing
ADLM 2025 focused on adding value in laboratory testing, ensuring the tests are meaningful to the patient’s clinical journey, and on improving the quality of results, focusing particularly on pre-analytical aspects, where 85% of errors occur.
The sessions on value-based testing highlighted the importance of clinical decision support tools in assisting clinicians to order the appropriate tests at the optimal testing frequency. These sessions offered practical advice, especially valuable at a time when laboratories face mounting pressure due to staffing shortages and increased test volumes.
In addition to his micro-lecture, Dr Bhrugu Yagnik also presented a poster on current US testing practices for Multiple Myeloma, highlighting the opportunities for laboratories to enhance testing and ensure guideline compliance.
The data in this study demonstrate that diagnostic testing in Multiple Myeloma is an area where laboratories can help physicians to provide value-based care through rational use of tests.
Closing remarks
Attending ADLM 2025 provided Binding Site the opportunity to meet with customers to understand the diagnostic testing that is important to them. We would like to thank everyone who visited the Thermo Fisher booth, interacted with us between sessions, or attended the mixer for their time and valuable input.
* The EXENT® System combines EXENT® Analyser with the Immunoglobulin Isotypes (GAM) for the EXENT® Analyser.
EXENT® is a registered trademark of The Binding Site Group Limited (Birmingham, UK) in certain countries. Product availability is subject to country specific regulatory requirements. Not for use in China.